GlassScriptPhysician profile
Stephanie Feely
NPI 1376901249
$8,089.35
in general payments reported to CMS, 2019-2025
32 companies · $636 in 2025
The $636 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,417 · 2022: $2,204 · 2023: $1,893 · 2024: $1,940 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,469.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,514.08 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,155.37 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $915.09 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $607.35 | 2022-2025 | |
| Glaxosmithkline, LLC. | $596.03 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $466.23 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.03 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $374.55 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $338.37 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $259.04 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.24 | 2022-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $171.21 | 2022 | |
| Abbott Laboratories | $140.54 | 2021-2025 | Freestyle Libre |
| Genzyme Corporation | $125.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.71 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $116.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $94.51 | 2021-2022 | |
| Axsome Therapeutics, INC. | $73.14 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $63.88 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $55.77 | 2023-2025 | Contrave, Onzetra Xsail |
| Phathom Pharmaceuticals, INC. | $55.58 | 2024 | Voquezna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $39.71 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $39.53 | 2022-2023 | Camzyos |
| Dexcom, INC. | $39.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.38 | 2023 | Xarelto |
| Advanced Oxygen Therapy INC. | $25.16 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.96 | 2021 | |
| Idorsia Pharmaceuticals US INC | $20.43 | 2024 | Quviviq |
| Seqirus USA INC | $19.88 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Vbi Vaccine (Delaware) INC. | $18.15 | 2023 | Prehevbrio |
| Teva Pharmaceuticals USA, INC. | $17.74 | 2021 | |
| Amarin Pharma, INC. | $16.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Feely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.